Epigenetic targeting is an area of growing interest in cancer treatment [43] and KDM1A overexpression is usually associated with poor prognosis, stemness maintenance, epithelial-to-mesenchymal transition (EMT), and escape of immune surveillance in a variety of cancers [17]. This evidence concerns the gene KDM1A and cancer.